文献速递心力衰竭与心肌病

乙酰唑胺在急性失代偿性心力衰竭不同左室射血分数谱中的减容效果:ADVOR试验预设分析

Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
PubMed 文献 · Circulation · 2022-11-06

ADVOR试验预设分析纳入519例急性心衰伴容量超负荷患者,随机接受静脉乙酰唑胺(500 mg每日一次)或安慰剂,叠加标准化静脉袢利尿剂。结果显示乙酰唑胺改善成功减容(OR 1.77, 95%CI 1.18-2.63, P=0.005),且效果不随基线LVEF分层(≤40%或>40%)或连续LVEF变化而改变(交互P均>0.401)。

要点

  • 乙酰唑胺在急性心衰减容中获益不受基线LVEF影响。
  • 乙酰唑胺提高利尿和排钠反应,缩短住院时间。
  • LVEF≤40%患者年龄更轻、男性更多、缺血性心脏病比例更高。

核心结论

  • 在急性失代偿性心衰患者中,乙酰唑胺叠加袢利尿剂可改善成功减容率和利尿反应,并缩短住院时间,且获益不随基线LVEF改变。

研究设计与样本

  • ADVOR试验为随机、双盲、安慰剂对照研究,共纳入519例急性心衰伴临床容量超负荷体征、NTproBNP>1000 ng/L或BNP>250 ng/mL的患者。
  • 患者随机接受静脉乙酰唑胺500 mg每日一次或安慰剂,叠加标准化静脉袢利尿剂(为口服维持剂量的两倍),按LVEF≤40%或>40%分层随机。

主要发现

  • 中位LVEF为45%(25th-75th百分位:30%-55%),43%的患者LVEF≤40%。
  • 乙酰唑胺对主要终点成功减容的总体获益OR为1.77(95%CI 1.18-2.63;P=0.005),按LVEF分层(≤40%或>40%)、按HFrEF/HFmrEF/HFpEF分类或连续LVEF评估时交互P均>0.401。
  • 乙酰唑胺改善利尿反应(累积尿量和排钠增加)并缩短住院时间,交互P均>0.160。

关键数值与推荐

  • 主要终点成功减容定义为随机后3天内无容量超负荷体征且无需因尿量不佳而强制升级减容治疗。
  • LVEF≤40%患者与较低LVEF相关特征:更年轻、男性更多、缺血性心脏病患病率更高、NTproBNP更高、房颤更少、eGFR更低。

临床怎么用

  • 对于急性失代偿性心衰伴容量超负荷患者,可考虑在静脉袢利尿剂基础上加用乙酰唑胺500 mg每日一次以促进减容。
  • 乙酰唑胺的减容获益不依赖于基线LVEF,可跨射血分数谱应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF). METHODS: This is a prespecified analysis of the randomized, double-blind, placebo-controlled ADVOR trial that enrolled 519 patients with acute heart failure (HF), clinical signs of volume overload (eg, edema, pleural effusion, or ascites), NTproBNP (N-terminal pro-B-type natriuretic peptide) >1000 ng/L, or BNP (B-type natriuretic peptide) >250 ng/mL to receive intravenous acetazolamide (500 mg once daily) or placebo in addition to standardized intravenous loop diuretics (twice that of the oral home maintenance dose). Randomization was stratified according to LVEF (≤40% or >40%). The primary end point was successful decongestion, defined as the absence of signs of volume overload within 3 days from randomization without the need for mandatory escalation of decongestive therapy because of poor urine output. RESULTS: Median LVEF was 45% (25th to 75th percentile; 30% to 55%), and 43% had an LVEF ≤40%. Patients with lower LVEF were younger and more likely to be male with a higher prevalence of ischemic heart disease, higher NTproBNP, less atrial fibrillation, and lower estimated glomerular filtration rate. No interaction on the overall beneficial treatment effect of acetazolamide to the primary end point of successful decongestion (OR, 1.77 [95% CI, 1.18-2.63]; P=0.005; all P values for interaction >0.401) was found when LVEF was assessed per randomization stratum (≤40% or >40%), or as HF with reduced ejection fraction, HF with mildly reduced ejection fraction, and HF with preserved ejection fraction, or on a continuous scale. Acetazolamide resulted in improved diuretic response measured by higher cumulative diuresis and natriuresis and shortened length of stay without treatment effect modification by baseline LVEF (all P values for interaction >0.160). CONCLUSIONS: When added to treatment with loop diuretics in patients with acute decompensated HF, acetazolamide improves the incidence of successful decongestion and diuretic response, and shortens length of stay without treatment effect modification by baseline LVEF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03505788.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Martens, Dauw, Verbrugge, et al. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. Circulation. 2022. PMID: 36335479. doi:10.1161/CIRCULATIONAHA.122.062486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。